IMCYSE
Imcyse is a clinical stage biopharmaceutical company pioneering the development of a new class of active specific immunotherapies for the treatment of severe chronic autoimmune diseases. The company’s unique technology platform allows it to locally target immune cells involved in the destruction of the diseased organ. This platform is based on the administration of Imotopes™, which are specifically modified peptides, allowing for the generation of cytolytic CD4 T-cells, that specifically eli... minate antigen-presenting cells and autoantigen specific lymphocytes. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no current therapeutic alternative and to potentially cure patients without impairing immune defense. The company has established proof of concept in several indications and has completed its first clinical trial in type 1 diabetes with promising results. Beyond type 1 diabetes, Imcyse is developing a pipeline of Imotopes™ for the treatment of several autoimmune diseases.
IMCYSE
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2010-01-01
Address:
Liège, Liege, Belgium
Country:
Belgium
Website Url:
http://www.imcyse.com
Total Employee:
11+
Status:
Active
Total Funding:
55.9 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Content Delivery Network Font Awesome Apache Euro
Current Employees Featured
Founder
Investors List
Biogenosis
Biogenosis investment in Series B - Imcyse
Epimède SA
Epimède SA investment in Series B - Imcyse
Pfizer
Pfizer investment in Series B - Imcyse
Meusinvest (Noshaq)
Meusinvest (Noshaq) investment in Series B - Imcyse
S.R.I.W.
S.R.I.W. investment in Series B - Imcyse
University of Leuven
University of Leuven investment in Series B - Imcyse
SFPI-FPIM
SFPI-FPIM investment in Series B - Imcyse
W.IN.G
W.IN.G investment in Grant - Imcyse
SFPI-FPIM
SFPI-FPIM investment in Series B - Imcyse
Belfius Bank
Belfius Bank investment in Debt Financing - Imcyse
Official Site Inspections
http://www.imcyse.com Semrush global rank: 2.8 M Semrush visits lastest month: 5.78 K
- Host name: cluster006.ovh.net
- IP address: 213.186.33.17
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "Imcyse"
Imcyse - specific active immunotherapeutics
Imcyse is a clinical-stage biopharmaceutical company committed to advancing the development of a new class of specific immunotherapies. Focused on severe autoimmune diseases, the …See details»
About us - Imcyse
The Imcyse journey began when the founders discovered the ability of certain peptides to stimulate the immune system in a new way. After further investigation they invented new peptides, called Imotopes TM and showed these could …See details»
Imcyse - Crunchbase Company Profile & Funding
Imcyse is a clinical stage biopharmaceutical company pioneering the development of a new class of active specific immunotherapies for the treatment of severe chronic autoimmune diseases. The company’s unique technology …See details»
ImCyse Company Profile 2024: Valuation, Funding & Investors
ImCyse General Information Description. Developer of therapeutic vaccines designed to offer treatment of multiple sclerosis and diabetes. The company's vaccines help to destroy locally …See details»
Imcyse SA - LinkedIn
Imcyse SA | 4,892 followers on LinkedIn. Pioneering the development of Imotopesâ„¢ to prevent, stop and potentially cure autoimmune diseases | Imcyse is a clinical-stage biopharmaceutical company ...See details»
Imcyse - Funding, Financials, Valuation & Investors - Crunchbase
Developing disease specific immune therapies to treat severe, chronic auto-immune, inflammatory, allergic, infectious diseases and tumors.See details»
Imcyse - EQT Group
Nov 22, 2024 imcyse.com. Sector. Healthcare. Country. Belgium. Fund. LSP 6. Entry. 2019. Web. imcyse.com. Latest news. 29 November 2024 EQT Exeter completes Spanish student housing portfolio sale to Azora; 26 November …See details»
Imcyse Company Profile - Office Locations, Competitors, Revenue …
Imcyse has 5 employees across 2 locations, $46.57 m in total funding, and €453.45 k in annual revenue in FY 2021. See insights on Imcyse including office locations, competitors, revenue, …See details»
Imcyse appoints new Scientific Advisory Board and opens new ...
Imcyse is a clinical stage biopharmaceutical company pioneering the development of a new class of active specific immunotherapies for the treatment of severe chronic autoimmune diseases. …See details»
Imcyse Raises €21.3M for Therapies in MS, Other Autoimmune …
Imcyse has raised €21.3 million ($25.8 million) in funding to advance its innovative immunotherapy platform for the treatment of multiple sclerosis (MS) and other severe …See details»
Imcyse announces a research collaboration with Pfizer Inc. in ...
Jan 8, 2018 Imcyse’s unique Imotopesâ„¢ are specific modified peptides that induce a unique type of T-cell. Known as cytolytic T-cells, these actively and specifically kill immune cells …See details»
Imcyse closes €21.3m Series B as new partner Pfizer takes equity …
Feb 19, 2021 Imcyse’s lead programme is for type 1 diabetes (T1D). Phase II studies of novel insulin-based Imotope IMCY-0098 are expected to begin in the third quarter of 2021. Imcyse …See details»
Imcyse Announces First Patient Dosed in Adaptive Phase 1/2
Apr 13, 2022 Imcyse is a clinical stage biopharmaceutical company pioneering the development of a new class of active specific immunotherapies for the treatment of severe chronic …See details»
Imcyse Announces First Patient Dosed in Adaptive Phase 1/2 …
Apr 13, 2022 IMCY-MS-001 study aims to determine safety profile, optimal dosing regimen and initial efficacySecond Imotopeâ„¢ from proprietary technology platform moves into clinic; interim …See details»
Pipeline - Imcyse
Imcyse is initially applying its Imotope TM technology for the treatment of severe, chronic autoimmune diseases where no therapeutic cures are available and existing therapies …See details»
Imcyse Announces Completion of Enrollment in Phase 1
Sep 13, 2023 “Completing enrollment in the Phase 1 trial with IMCY-0141 is an important step towards bringing this therapy to patients suffering from RRMS, a disease with devastating and …See details»
Imcyse Announces Completion of Enrollment in Phase 1 Clinical …
Sep 13, 2023 Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune …See details»
First-in-human, double-blind, randomized phase 1b study of
Jun 21, 2024 Background: IMCY-0098, a synthetic peptide developed to halt disease progression via elimination of key immune cells in the autoimmune cascade, has shown a …See details»
Imcyse Reports Positive Immune Response from Interim Analysis …
Imcyse S.A. Thu, Jan 13, 2022, 7:00 AM 4 min read Positive interim biomarker data supports specific immune signature induced by IMCY-0098 and effect on potentially pathogenic T cellsSee details»
News & Events - Imcyse
Mar 14, 2022 Imcyse Announces First Patient Dosed in Adaptive Phase 1/2 Clinical Trial of Imotopeâ„¢ IMCY-0141 for Multiple Sclerosis. Read more. March 14, 2022. Imcyse to Present …See details»